Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
To read the full story
Related Article
- Choseido’s Cymbalta Generic Now Available in Japan
September 13, 2021
- Kyosomirai, Nissin Roll Out Cymbalta Generics
August 4, 2021
- Daiichi Sankyo Espha, Meiji Pharma Launch Cymbalta Generics
July 28, 2021
- Towa to Launch Cymbalta Generics on Aug. 30, Nipro on July 21/27
July 19, 2021
- Yoshindo Announces Shipment Curbs for Cymbalta Generics, 6 Other APIs
June 22, 2021
- Yoshindo’s Cymbalta Generics Out, but Supply Restrictions in Place: Sources
June 21, 2021
- Kyowa Adjusting Cymbalta Generic Supply before Launch as Rivals Delay Release
June 18, 2021
- 9 Drugs Face Generic Entries, AGx Debuts for 2 Brands: June Listing
June 17, 2021
- 17 Firms Get Approval for Cymbalta Generics, June Listing Eyed
February 16, 2021
BUSINESS
- Chugai’s Q1 Sales Drop 24% on End of Ronapreve Govt Purchase and Generic Competition
April 25, 2024
- Leqembi Gathers Pace with Sales Up 2.7-Fold in January-March: Eisai
April 25, 2024
- Astellas Reels in EU Nod for Xtandi Use in Earlier Setting
April 25, 2024
- Novo Japan’s Revenue Hits Record Yet Again in 2023 with 8.5% Growth
April 25, 2024
- Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief
April 25, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…